Login / Signup

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis.

Laura Maria FuhrNina HankeBernd MeibohmThorsten Lehr
Published in: Clinical pharmacokinetics (2021)
A comprehensive and mechanistic PBPK/PD model to study dabigatran reversal has been established, which includes whole-body PBPK modeling of idarucizumab, the idarucizumab-dabigatran interaction, dabigatran hemodialysis, the pharmacodynamic effect of dabigatran on blood coagulation, and the impact of renal function in these different scenarios. The model was applied to explore different reversal scenarios for dabigatran therapy.
Keyphrases
  • atrial fibrillation
  • climate change
  • chronic kidney disease
  • peritoneal dialysis
  • end stage renal disease
  • bone marrow
  • data analysis